FDA approves first broad RAS-targeted drug for metastatic pancreatic cancer
The U.S. Food and Drug Administration approved Revolution Medicines' (RVMD) once-daily pill Rasonque daraxonrasib on August 26, marking the first broad RAS-targeted treatment for adults with previously treated metastatic pancreatic cancer. The drug nearly doubled median overall survival to 13.2 months in a Phase 3 trial compared to standard chemotherapy's 6.7 months and reduced the risk of death by 60%. Pancreatic cancer is notoriously difficult to treat, often driven by mutated RAS proteins that have long been an elusive target for drug development. The FDA fast-tracked approval through its Commissioner’s National Priority Voucher program due to the disease's severity. Over 2,000 patients had already accessed the drug via expanded access programs before full clearance. Revolution Medicines transitioned from a clinical-stage company with $3.9 billion in cash reserves into one selling an approved therapy at $39,800 per month wholesale price. Despite historic data and rapid approval, RVMD's stock remained flat near $211.70 as the market had already priced in expectations based on prior trial disclosures.
Tickers: $RVMD